Active, not recruitingNCT03045029
ADAPT - A Patient Registry of the Real-world Use of Orenitram®
Studying Drug- or toxin-induced pulmonary arterial hypertension
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- United Therapeutics
- Intervention
- Oral treprostinil(drug)
- Enrollment
- 300 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2025
Study locations (30)
- University of California - San Francisco, Fresno, California, United States
- University of Southern California - Keck Medical Center, Los Angeles, California, United States
- Paloma Medical Group, San Juan Capistrano, California, United States
- Santa Barbara Pulmonary Associates, Santa Barbara, California, United States
- Harbor UCLA Medical Center, Torrance, California, United States
- Aurora Denver Cardiology Associates, Aurora, Colorado, United States
- Pueblo Pulmonary Associates, Pueblo, Colorado, United States
- Lung Associates PA, Bradenton, Florida, United States
- University of Florida Clinical Research Center, Gainesville, Florida, United States
- St. Vincent's Lung, Sleep, and Critical Care Specialists, Jacksonville, Florida, United States
- AdventHealth Orlando, Orlando, Florida, United States
- Central Florida Pulmonary Group, P.A., Orlando, Florida, United States
- USF South Florida Heart Health, Tampa, Florida, United States
- Cleveland Clinic Florida, Weston, Florida, United States
- Piedmont Healthcare/Research, Austell, Georgia, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03045029 on ClinicalTrials.govOther trials for Drug- or toxin-induced pulmonary arterial hypertension
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06872112A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial HypertensionJoseph C. Wu
- RECRUITINGPHASE2NCT06351345129 Xenon Imaging in Patients Treated With SotaterceptBastiaan Driehuys
- RECRUITINGPHASE4NCT07140484Sotatercept in Pulmonary Arterial HypertensionUniversity of Alberta
- RECRUITINGPHASE2NCT07175038A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)AllRock Bio, Inc.
- RECRUITINGNCT07013149The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial HypertensionUniversity of Sao Paulo General Hospital
- RECRUITINGNCT06998329PulmonAry hyperteNsion DiagnOsis: a National cohoRt reseArchUniversity of Sao Paulo General Hospital
- ENROLLING BY INVITATIONPHASE2NCT06992440Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial HypertensionGustavo A Heresi, MD, MS
- RECRUITINGNANCT06968962Comparison of Sequential to Initial Combination Therapy in PAHSecond Affiliated Hospital, School of Medicine, Zhejiang University
See all trials for Drug- or toxin-induced pulmonary arterial hypertension →